Kitaadachi-gun, Japan Clinical Trials

A listing of Kitaadachi-gun, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

Research Site
 (0.7 away) Contact site
  • 0 views
  • 26 Sep, 2021
  • +206 other locations
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn about regorafenib taken together with nivolumab …

Saitama Cancer Center
 (0.7 away) Contact site
  • 0 views
  • 25 Sep, 2021
  • +42 other locations
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

neutrophil count
invasive bladder cancer
conjugated bilirubin
gemcitabine
bladder tumor
Saitama Medical University Hospital
 (7.4 away) Contact site
  • 15 views
  • 23 Sep, 2021
  • +320 other locations
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

durvalumab
carcinoma
fluorouracil
squamous cell carcinoma
capecitabine
Research Site
 (0.7 away) Contact site
  • 1 views
  • 11 Sep, 2021
  • +122 other locations
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

monoclonal antibodies
oxaliplatin
immunoglobulin
cancer
adenocarcinoma
Research Site
 (0.7 away) Contact site
  • 0 views
  • 15 Sep, 2021
  • +153 other locations
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits …

stroke
heart failure
heart disease
diuretic therapy
b-type natriuretic peptide
Ageo Central General Hospital
 (3.0 away) Contact site
  • 16 views
  • 26 Sep, 2021
  • +784 other locations
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US patients with prior TNFi failure or intolerance will be enrolled. Outside of the US, TNFi nave and TNFi experienced patients will be enrolled. …

tumor necrosis factor
sulfasalazine
hematochezia
remission
cancer
Saitama Children's Medical Center
 (7.5 away) Contact site
  • 0 views
  • 07 Sep, 2021
  • +31 other locations
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 …

chronic progressive multiple sclerosis
secondary progressive multiple sclerosis
contraceptive use
disease or disorder
Investigational Site Number 3920018
 (9.3 away) Contact site
  • 128 views
  • 23 Jul, 2021
  • +223 other locations
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free …

chemoradiotherapy
brachytherapy
adenosquamous carcinoma
cancer
adenocarcinoma
Saitama Cancer Center ( Site 1169)
 (0.7 away) Contact site
  • 87 views
  • 23 Sep, 2021
  • +165 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

chemoradiotherapy
leucovorin
ebrt
adenocarcinoma
squamous cell carcinoma
Saitama Cancer Center ( Site 0564)
 (0.7 away) Contact site
  • 32 views
  • 26 Sep, 2021
  • +152 other locations